Pacira BioSciences, Inc. (PCRX) |
| 23.75 -0.31 (-1.29%) 04-14 16:00 |
| Open: | 23.87 |
| High: | 24.375 |
| Low: | 23.69 |
| Volume: | 294,642 |
| Market Cap: | 1,022(M) |
| PE Ratio: | 148.44 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 28.47 |
| Resistance 1: | 24.38 |
| Pivot price: | 23.18 |
| Support 1: | 22.39 |
| Support 2: | 21.16 |
| 52w High: | 27.64 |
| 52w Low: | 18.8 |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| EPS | 0.160 |
| Book Value | 16.860 |
| PEG Ratio | 0.00 |
| Gross Profit | 11.345 |
| Profit Margin (%) | 0.97 |
| Operating Margin (%) | -1.17 |
| Return on Assets (ttm) | 1.5 |
| Return on Equity (ttm) | 1.0 |
Mon, 13 Apr 2026
Pacira (PCRX) Data Highlights Cost Benefits and Opioid Reduction - GuruFocus
Mon, 13 Apr 2026
Pacira (PCRX) Highlights Economic Benefits of Exparel in Orthope - GuruFocus
Mon, 13 Apr 2026
Hip replacement patients with back pain used fewer opioids with EXPAREL - Stock Titan
Mon, 13 Apr 2026
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures - Sahm
Fri, 10 Apr 2026
PCRX.O Technical Analysis & Stock Price Forecast - Intellectia AI
Thu, 09 Apr 2026
Dimensional Fund Advisors (NASDAQ: PCRX) reports 2.06M shares owned - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |